EphA3, a novel target for leukaemia stem cell therapy [ 2016 - ]

Research Grant

Researchers: Dr Christopher Slape (Principal investigator) ,  E/Pr Andrew Boyd

Brief description Patients with acute myeloid leukaemia often respond to therapy, but many relapse due to “leukemic stem cells” (LSC), the few cells in the original leukaemia which survive therapy. We focus on a protein (EphA3) which sits on LSCs and helps them interact with their environment. Disrupting this interaction may make these cells vulnerable to therapy. We aim to determine the function of EphA3 on LSCs and optimise the therapeutic use of an antibody against EphA3 which is currently in clinical trial.

Funding Amount $616,992.00

Funding Scheme Project Grants

Notes Standard Project Grant